We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics

DIAGNOSTICA STAGO

Offers a complete system of hemostasis instrumentation and optimized reagent kits for research, as well as for routin... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
27 Oct 2020 - 31 Oct 2020
Virtual Venue
28 Oct 2020 - 30 Oct 2020
Virtual Venue

Elevated Clotting Factor V Found with Severe COVID-19

By LabMedica International staff writers
Posted on 08 Oct 2020
Print article
Image: The ACL TOP 750 analyzer is for advanced automation and quality management in hemostasis testing (Photo courtesy of Instrumentation Laboratory).
Image: The ACL TOP 750 analyzer is for advanced automation and quality management in hemostasis testing (Photo courtesy of Instrumentation Laboratory).
Coagulopathy causes morbidity and mortality in patients with coronavirus disease 2019 (COVID‐19) due to severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) infection. Most doctors now know that COVID-19 can cause blood clots, potentially leading to paralysis, stroke, heart attack and death.

Hypothesized mechanisms for thrombosis invoke inflammation, endothelial dysregulation, patient immobilization, antiphospholipid antibodies, and coagulation factor VIII dysregulation. However, direct links between the SARS‐CoV‐2 virus and coagulopathy remain unmapped. Common laboratory findings include elevations of D‐dimer and the acute phase reactants fibrinogen and factor VIII.

Medical Scientists in the coagulation laboratory at the Massachusetts General Hospital (Boston, MA, USA) and their colleagues collected patient specimens in a prospective cohort study over approximately one month at the beginning of the COVID‐19 pandemic in Massachusetts, USA (March 23, 2020 to April 27, 2020). The team studied more than 100 patients treated in the intensive care unit for COVID-19. For factors V, X, and VIII, D‐dimer, and fibrinogen they also retrospectively obtained historical values from patients with specimens submitted to our laboratory prior to the COVID‐19 pandemic.

The scientists measured Factor V, VIII, and X activities and activated partial thromboplastin time (aPTT) waveforms in the same leftover clinical specimens using validated clinical laboratory assays. Prothrombin time (PT), aPTT, heparinase aPTT (Stago, Asnieres, France), and the activities of factors II, VII, IX, XI, and XII were recorded only if determined on a specimen collected within six hours of the study specimen.

Both D‐dimer (bioMérieux, Marcy‐l'Étoile France) and fibrinogen (Stago) values were recorded at the closest time point to the study specimen and were only included if they were measured within two days of the study specimen. Factor assays were one‐stage, PT‐based for factors II, V, VII and X, and aPTT‐based for factors VIII, IX, XI, and XII, using an ACL TOP 750 analyzer, Hemosil calibrator, Synthasil or Recombiplastin, all from Instrumentation Laboratory (Bedford MA, USA), and factor‐deficient plasma from Precision Biologic (Dartmouth, NS, Canada).

The study found that patients with elevated factor V were more likely to have blood clots in the lungs, called pulmonary embolism, and deep vein thrombosis (DVT), or clots in the veins. Of patients with high levels of factor V, one-third had either DVT or a pulmonary embolism, compared with 13% of patients with lower levels. While patients with high factor V levels were at greater risk for clotting problems, patients with lower factor V levels had a higher risk of death. A decrease in factor V levels might indicate patients are progressing to a serious and often fatal condition in which clotting processes become overactive.

The authors concluded that their study revealed factor V perturbations as a previously unrecognized feature of severe COVID‐19, adds a mechanistic candidate to ongoing investigations of COVID‐19 coagulopathy with potential links to SARS‐CoV‐2 disease biology. The study was first published on August 24, 2020 in the American Journal of Hematology.

Related Links:
Massachusetts General Hospital
Stago
bioMérieux
Instrumentation Laboratory
Precision Biologic




Print article
BIOHIT  Healthcare OY

Channels

Molecular Diagnostics

view channel
Image: Photomicrograph of histology of a Ewing sarcoma in lung. The PAS stain highlights glycogen and the staining was negative with a PAS diastase stain (Photo courtesy of Nephron).

Comprehensive Molecular Profiling Matches Pediatric Patients to Therapies

A major challenge of using a comprehensive profiling approach for precision medicine is separating pathogenic from non-pathogenic molecular changes within a tumor. A program has been presented of the... Read more

Industry News

view channel
Image: Mindray Hematology Solution Helps High-Volume Lab Run 2,820,000 CBC Tests Annually (Photo courtesy of Mindray)

Mindray Hematology Solution Helps High-Volume Lab Run 2,820,000 CBC Tests Annually

High-volume laboratories face several challenges, including high instrument failure rate, errors due to several manual steps, low efficiency and long TAT, and heavier workload for the lab staff.... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.